SEARCH

SEARCH BY CITATION

References

  • 1
    Azam, M., Lee, C., Strehlow, I. & Schindler, C. (1997) Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity, 6, 691701.
  • 2
    Backs, B., Broeders, L., Hoefsloot, L.H., Wognum, B. & Löwenberg, B. (1996) Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia, 10, 466472.
  • 3
    Backs, B., Broeders, L. & Löwenberg, B. (1992) Kit ligand rescue in vitro erythropoiesis in myelodysplastic syndromes. Blood, 80, 12131218.
  • 4
    Bouscary, D., De Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F. & Fontenay-Roupie, M. (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukaemia, 11, 839845.
  • 5
    Brada, S., De Wolf, J., Hendricks, D., Esselink, M., Ruiters, M. & Vellenga, E. (1996) The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36 sorted bone marrow cells of myelodysplasia patients. Blood, 88, 505510.
  • 6
    Callus, B.A. & Mathey-Prevot, B. (1998) Interleukin-3-induced activation of the Jak/STAT pathway is prolonged by proteasome inhibitors. Blood, 91, 31823192.
  • 7
    Chretien, S., Varlet, P., Verdier, F., Gobert, S., Cartron, J.P., Gisselbrecht, S., Mayeux, P. & Lacombe, C. (1996) Erythropoietin-induced erythroid differentiation in the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO Journal, 15, 41744181.
  • 8
    Dai, C.H., Price, J.O., Brunner, T. & Krantz, S.B. (1998) Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cells apoptosis. Blood, 91, 12351242.
  • 9
    Damen, J.E., Wakao, H., Miyajima, A., Krosl, J., Humphries, K.R., Cutler, R.L. & Kristal, G. (1995) Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO Journal, 14, 55575568.
  • 10
    Dumon, S., Constantino Rosa Santos, S., Debierre-Grockiego, F., Gouilleux-Gruart, V., Cocault, L., Boucheron, C., Mollat, P., Gisselbrecht, S. & Gouilleux, F. (1999) IL-3 dependent regulation of Bcl-XL gene expression by STAT5 in a bone marrow derived cell line. Oncogene (in press).
  • 11
    Dusanter-Fourt, I., Casadevall, N., Lacombe, C., Muller, O., Billat, C., Fischer, S. & Mayeux, P. (1992) Erythropoietin induces the tyrosine phosphorylation of its own receptor in erythropoietin-responsive cells. Journal of Biological Chemistry, 267, 1067010675.
  • 12
    Gersuk, G.M., Beckham, C., Loken, M.R., Kiener, P., Anderson, J.E., Farrand, A., Troutt, A.B., Ledbetter, J.A. & Deeg, H.J. (1998) A role for tumor necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplatic syndrome. British Journal of Haematology, 103, 17688.
  • 13
    Gobert, S., Chretien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt, I., Groner, B., Lacombe, C., Gisselbrecht, S. & Mayeux, P. (1996) Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO Journal, 15, 24343441.
  • 14
    Gregoli, P.A. & Bondurant, M.C. (1997) The roles of Bcl-XL and apopain in the control of erythropoiesis by erythropoietin. Blood, 90, 630640.
  • 15
    Gupta, P., Niehans, G.A., LeRoy, S.C., Gupta, K., Morrison, V.A., Schultz, C., Knapp, D.J. & Kratzke, R.A. (1999) Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 13, 4453.
  • 16
    Hoefsloot, L.H., Van Amelsvoort, M.P., Broeders, L.C.A.M., Van Der Plas, D.C., Van Lom, K., Hoogerbrugge, H., Touw, I.P. & Löwenberg, B. (1997) Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood, 89, 16901700.
  • 17
    Iwatsuki, K., Endo, T., Misawa, H., Yokouchi, M., Matsumoto, A., Ohtsubo, M., Mori, K.J. & Yoshimura, A. (1997) STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. Journal of Biological Chemistry, 272, 81498152.
  • 18
    Jeffers, M., Taylor, G.A., Wegner, K.M., Omura, S. & Van de Woude, G.F. (1997) Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Molecular and Cellular Biology, 17, 799808.
  • 19
    Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R. & Hirokawa, K. (1997) Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukaemia, 11, 20492054.
  • 20
    Klingmüller, U., Wu, H., Hsia, J.G., Toker, A., Duckworth, B.C., Cantley, L.C., & Lodish, H.F. (1997) Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proceedings of the National Academy of Sciences of the United States of America, 94, 30163021.
  • 21
    Koury, M.J. & Bondurant, M.C. (1990) Erythropoietin retards DNA breakdown and prevents programmmed cell death in erythroid progenitor cells. Science, 248, 378381.
  • 22
    Krantz, S.B. (1991) Erythropoietin. Blood, 77, 419434.
  • 23
    Lepelley, P., Grardel, N., Erny, O., Iaru, T., Obein, V., Cosson, A. & Fenaux, P. (1998) Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leukemia and Lymphoma, 30, 307312.
  • 24
    Maciejewski, J., Selleri, C., Anderson, S. & Young, N.S. (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 31833190.
  • 25
    Meyer, J., Jücker, M., Ostertag, W. & Stocking, C. (1998) Carboxyl-truncated STAT5β is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood, 91, 19011908.
  • 26
    Mittelman, M., Gardyn, J., Carmel, M., Malovani, H., Barak, Y. & Nir, U. (1996) Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leukemia Research, 20, 459466.
  • 27
    Mori, S., Tanaka, K., Omura, S. & Saito, Y. (1995) Degradation process of ligand-stimulated platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway. Journal of Biological Chemistry, 270, 2944729452.
  • 28
    Okada, M., Okamoto, T., Saheki, K., Fujimori, Y., Takemoto, Y. & Kakisita, E. (1997) Increased expression of Fas antigen and apoptosis in patients with myelodysplastic syndromes. Blood, 90, (Suppl. 1), 227a.
  • 29
    Parker, J.E., Fishlock, K.L., Mijovic, A., Pagliuca, A. & Mufti, G.J. (1997) Leukemic progression in myelodysplastic syndromes (MDS) is associated with decreased apoptosis and a reduced ratio of pro- versus anti-apoptotic Bcl-2 related proteins. Blood, 90, (Suppl. 1), 520a.
  • 30
    Parker, J.E. & Mufti, G.J. (1998) Ineffective haematopoiesis and apoptosis in myelodysplastic syndromes. British Journal of Haematology, 101, 220230.
  • 31
    Rajapaksa, R., Ginzton, N., Rott, L.S. & Greenberg, P. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 42754287.
  • 32
    Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S., & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268276.
  • 33
    Silva, M., Grillot, D., Benito, A., Richard, C., Nunez, G. & Fernandez-Luna, J.L. (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood, 88, 15761582.
  • 34
    Teglund, S., McKay, C., Schuetz, E., Van Deursen, J.M., Stravopodis, D., Wang, D., Brown, M., Brodner, S., Grosveld, G. & Ihle, J.N. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell, 93, 841850.
  • 35
    Verdier, F., Chrétien, S., Muller, O., Varlet, P., Yoshimura, A., Gisselbrecht, S., Lacombe, C. & Mayeux, P. (1998) Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Journal of Biological Chemistry, 273, 2818528190.
  • 36
    Witthuhn, B., Quelle, F.W., Silvennoinen, O., Yi, T., Tang, B., Miura, O. & Ihle, J.N. (1993) Jak2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 74, 227236.
  • 37
    Wu, H., Klingmüller, U., Acurio, A., Hsiao, J.G. & Lodish, H.F. (1997) Functional interactions of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proceedings of the National Academy of Sciences of the United States of America, 94, 18061810.
  • 38
    Wu, H., Liu, X., Jaenisch, R. & Lodish, H.F. (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell, 83, 5968.
  • 39
    Yu, C.L. & Burakoff, S.J. (1997) Involvement of proteasomes in regulating Jak-STAT pathways upon IL-2 stimulation. Journal of Biological Chemistry, 272, 1401714020.